Searched for
NOVO NORDISK CEO
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- India's GCC model shifts from cost to capability as AI, talent strains biteIndia's dominance in global capability centres is evolving. These hubs are now integrated, managing complex functions beyond support. Risin...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapyLast October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of the therap...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Acquisition count rises: Inside OpenAI's major deals in 2026The AI major’s half a dozen deals in the first quarter underscore its push to strengthen its position across enterprise software, developer...
- Emcure slashes prices of weight management drug Poviztra by up to 55%Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...
- Eli Lilly Foundayo weight loss pill price, side effects, dosage, treatment: When will sales for oral weight-loss drug begin?Foundayo Eli Lilly weight loss pill: Eli Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral m...
- Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo NordiskThe US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Nov...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
- NVO stock crashes 14%: Why Novo Nordisk shares are down today? 2026 sales forecast and Eli Lilly competition explainedNVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...
- Novo Nordisk Stock Share Price Today: Why company's shares are down? Here's Alzheimer drug’s trial outcome, stock market impact, analysts insightsNovo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to slow Alzheime...
- Pfizer to acquire obesity drug startup Metsera in $10 billion dealPfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move mark...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- Wegovy maker Novo's profit warning triggers $70 billion share routNovo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO....
- Novo Nordisk stock plunges 23% after cutting sales forecast and naming Mike Doustdar as new CEONVO stock today: Novo Nordisk's stock plummeted over 23% following a reduced full-year sales forecast and the announcement of Maziar Mike D...
- Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEONovo Nordisk has a new CEO. Maziar Mike Doustdar takes the helm. This follows the departure of Lars Fruergaard Jorgensen. The company aims ...
- Obesity drug maker Novo Nordisk ousts CEO as competition weighsNovo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity d...
Load More
